Biomarker for diagnosis and prognosis of prostate cancer and application of biomarker

The invention relates to the technical field of biological medicine, in particular to a biomarker for diagnosis and prognosis of prostatic cancer and application of the biomarker. More specifically, the invention relates to a biomarker for diagnosis and prognosis of prostate cancer, and the biomarker is DHFRL1 and/or TMEM87A. The inventor has found that the expression level of DHFRL1 and TMEM87A in prostate cancer patients is obviously higher than that in healthy people. More particularly, the inventor finds that high-level expression of DHFRL1 and/or TMEM87A has good sensitivity and specificity when being used for diagnosing prostatic cancer and is related to prognosis of prostatic cancer patients, so that DHFRL1 and/or TMEM87A can be used as a biomarker for diagnosis and prognosis judgment of prostatic cancer. 本发明涉及生物医药技术领域，特别是涉及一种用于前列腺癌诊断和预后判断的生物标志物及其应用。更具体地，本发明涉及一种用于前列腺癌的诊断和预后判断的生物标志物，所述生物标志物是DHFRL1和/或TMEM87A。本发明人已发现，DHFRL1和TMEM87A在前列腺癌患者中的表达水平明显高于健康人群中的表达水平。更特别地，本发明人发现，DHFRL1和/或TMEM87A的高水平表达在用于诊断前列腺癌时具有良